Reactivation of the p53 pathway by MDM2 inhibition has been suggested as a promising therapeutic strategy in cancers retaining wild-type TP53 and several MDM2 antagonists are currently in clinical trials [104–107]. The gene discussed is MDM2; the disease is cancer.